plan to conduct our Phase 1, and possibly Phase 2, clinical trials for ZYN002 in Australia (subject to applicable regulatory approval), and do not expect at this time to file an
substantial and increasing net losses for the foreseeable future as we continue development of, and seek regulatory approvals for, ZYN002 and ZYN001;§We will need to raise additional capital to continue operations, including the
not necessarily be indicative of the results of the entire year.Statements of Operation Data:Years Ended December 31,Three Months EndedMarch 31,2013201420142015(unaudited)Revenues$943,904$810,012$146,287$14,828Operating expenses:Research and development1,134,0412,401,406285,725853,704General and administrative444,3024,076,33999,704653,773​​​​​​​​​​​​​​Total operating expenses1,578,3436,477,745385,4291,507,477​​​​​​​​​​​​​​Loss from operations(634,439)(5,667,733)(239,142)(1,492,649)Other income (expense):Interest (expense) income, net(2,351)(1,844)(1,217)680​​​​​​​​​​​​​​Net loss(636,790)(5,669,577)(240,359)(1,491,969)Accretion of redeemable convertible preferred stock(161,834)(87,954)(87,954)—​​​​​​​​​​​​​​Net loss applicable to common stockholders$(798,624)$(5,757,531)$(328,313)$(1,491,969)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Per share information:Net loss per share basic and diluted$(1.63)$(6.44)$(0.67)$(0.74)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Basic and diluted weighted average shares outstanding490,760894,575490,7602,029,747​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Pro forma net loss (unaudited)(1)$(5,669,577)$(1,491,969)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Pro forma net loss per share basic and diluted (unaudited)(1)$(2.56)$(0.26)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Pro forma basic and diluted weighted average shares outstanding (unaudited)(1)2,215,5075,733,963​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​(1)Refer
revenue and become profitable depends upon our ability to obtain regulatory approval for, and successfully commercialize, ZYN002, ZYN001 or other product candidates that we may develop, in-license or
operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for our
we anticipate incurring significant costs associated with commercializing our product candidates.We will require additional capital to fund our operations and if we fail to obtain necessary
approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;§the FDA may require development of a Risk Evaluation and Mitigation Strategy, or
almost entirely dependent upon these two product candidates, any such setback in our pursuit of regulatory approval would have a material adverse effect on our business and prospects.We plan to conduct clinical trials for ZYN002 and ZYN001 outside the United States and the FDA may
regulatory schema;§foreign exchange fluctuations;§manufacturing, customs, shipment and storage requirements;§cultural differences in medical practice and clinical research; and§diminished protection of intellectual property in some countries.Even if ZYN002 or ZYN001 receive regulatory approval, they may still face future development and
necessary approvals may delay the launch of our products and failure to comply with these laws and regulations may adversely affect the results of our business operations.ZYN002 and ZYN001 contain controlled substances as defined in the federal Controlled Substances Act of 1970, or CSA.
ZYN001 could have a material adverse effect on our business, results of operations and financial condition.Failure to obtain regulatory approval in jurisdictions outside the United States and the European
reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.In the United States there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could
obtain regulatory approval and successfully commercialize ZYN002, ZYN001 or other product candidates that we may develop, these new laws may result in additional reductions in Medicare and other
through third parties, our business, financial condition and results of operations could be materially adversely affected.Our product candidates, if approved, may be unable to achieve broad market acceptance and,
Any factors preventing or limiting the market acceptance of our product candidates could have a material adverse effect on our business, results of operations
For instance, the loss of preclinical data or data from any future clinical trial involving our product candidates could result in delays in our development and regulatory filing
proprietary information, we could incur liability and the development of our product candidates could be delayed.Risks Related to Our Dependence on Third PartiesWe rely on third parties to conduct our preclinical studies and clinical trials.
parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.We rely on CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies of our product
expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to